Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:53 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Extension Study to Assess Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis
NCT01103024 · Novartis · PHASE3 · withdrawn · last registry update 2020-09-29 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Core study in non-infectious active uveitis was terminated” | – | Registry record, Novartis |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL17A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-09-17Also stopped (terminated): Novartis Pharmaceuticals, AIN457 + ACZ885 (NCT01364389)
- 2021-09-08Also stopped (withdrawn): Massachusetts General Hospital, Secukinumab (NCT03866317)
- 2021-08-26Results posted on the registry: Novartis Pharmaceuticals, Placebo 2 mL auto-injector + Placebo 1 mL prefilled syringe (NCT03589885)
- 2021-08-25Phase 3 first posted: UCB Biopharma SRL, bimekizumab (NCT05020249)
- 2021-08-25Results posted on the registry: Northwestern University, Secukinumab + Placebo (NCT03041038)
- 2021-08-16Results posted on the registry: Novartis Pharmaceuticals, Experimental : Secukinumab low dose + Experimental: Secukinumab high dose (NCT02471144)
- 2021-08-13Results posted on the registry: Eli Lilly and Company, Ixekizumab (NCT03942042)
- 2021-08-02Results posted on the registry: Bond Avillion 2 Development LP, M1095 (Sonelokimab) + Placebo (NCT03384745)
- 2021-07-23Results posted on the registry: Novartis Pharmaceuticals, secukinumab low dose + secukinumab high dose (NCT03668613)
- 2021-07-13Results posted on the registry: AbbVie, risankizumab + secukinumab (NCT03478787)
- 2021-07-12Results posted on the registry: Novartis Pharmaceuticals, AIN457 (NCT01009281)
- 2021-07-12Also stopped (terminated): Novartis Pharmaceuticals, AIN457 (NCT01009281)
- 2021-06-25Results posted on the registry: Eli Lilly and Company, Ixekizumab + Placebo (NCT03364309)
- 2021-06-18Phase 3 first posted: Novartis Pharmaceuticals, Secukinumab 300 mg + Secukinumab 150 mg (NCT04930094)
- 2021-06-18Results posted on the registry: Eli Lilly and Company, Ixekizumab + Placebo (NCT03129100)
- 2021-06-07Results posted on the registry: Novartis Pharmaceuticals, secukinumab 150 mg (NCT03504852)
- 2021-05-28Also stopped (withdrawn): Wake Forest University Health Sciences, secukinumab 150 mg (2 injections per dose (NCT04274166)
- 2021-05-27Results posted on the registry: Novartis Pharmaceuticals, AIN457A (NCT01169844)
- 2021-05-25Phase 3 first posted: UCB Biopharma SRL, Bimekizumab (NCT04901195)
- 2021-03-30Results posted on the registry: Eli Lilly and Company, Mirikizumab + Placebo (NCT03535194)
- 2021-03-11Also stopped (terminated): Icahn School of Medicine at Mount Sinai, Secukinumab + Placebo (NCT02599129)
- 2021-02-25Results posted on the registry: Novartis Pharmaceuticals, a drug against IL17A (NCT03553823)
- 2021-02-03Phase 3 first posted: Novartis Pharmaceuticals, Secukinumab + Placebo (NCT04737330)
- 2021-02-01Phase 3 first posted: Novartis Pharmaceuticals, Secukinumab + Placebo (NCT04732117)
- 2021-01-28Results posted on the registry: Novartis Pharmaceuticals, Secukinumab 300 mg + Secukinumab 150 mg (NCT02798211)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision